Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma
(GBM) represents the most aggressive form among CNS malignancies.
This is a nationwide single-center phase II drug clinical trial with an approximate duration
of 32 months.
The clinical trial will be single-arm to evaluate the biological activity and effects of
metformin in combination with TMZ in patients with GBM.